U.S. biotechnology giant Amgen has officially retained an independent third-party research institution to conduct an un-biased evaluation of the clinical... Read more
Tag: #Global Trends
Takeda’s $4 billion TYK2 inhibitor zasocitinib outperforms Bristol Myers’ Sotyktu in head-to-head psoriasis trial
Japanese drugmaker Takeda has officially announced positive top-line readouts from a head-to-head clinical trial, demonstrating that its investigational autoimmune candidate,... Read more
J&J eyes rare disease expansion for future blockbuster Imaavy following successful Phase 2/3 anemia trial
Johnson & Johnson (J&J) has unveiled positive data from its pivotal Phase 2/3 clinical trial, designated as the Energy study,... Read more
Novo Nordisk reports internal IT data breach, advising clinical trial patients to ‘remain vigilant’
Danish pharmaceutical giant Novo Nordisk has officially issued a security incident notice confirming a targeted cyberattack that compromised specific components... Read more
DKSH enters strategic distribution compact with BridgeBio for rare cardiac therapy in selected Asia Pacific markets
DKSH has officially entered into a definitive strategic distribution and commercialization partnership with BridgeBio, a U.S. biotechnology innovator focused on... Read more
NICE clears AbbVie’s migraine drug Aquipta for acute NHS reimbursement in England and Wales
The National Institute for Health and Care Excellence (NICE) has published final draft guidance enabling AbbVie’s Aquipta (atogepant) to be... Read more
European Medicines Agency validates Bayer’s asundexian application — First Factor XIa inhibitor enters regulatory assessment for stroke prevention
German life science enterprise Bayer has officially announced that the European Medicines Agency (EMA) has validated and initiated its centralized... Read more
Parabilis Medicines sets historic biotech record with $670 million US IPO
U.S. biotechnology innovator Parabilis Medicines has successfully secured the largest initial public offering (IPO) in global biotech history. The landmark... Read more
FDA clears expanded indications for Organon’s Tofidence to treat cytokine release syndrome and COVID-19
Organon has officially announced that the U.S. Food and Drug Administration (FDA) has approved the expanded clinical utilization of its... Read more









